Clinical trials: Digestive Disease
Cystic Fibrosis
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy…
- Trial name
- ABCI (NCT05802264)
- Testing
- ABCI
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Cystetic Medicines, Inc.
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine…
- Trial name
- VISTA-1 (NCT06824064)
- Testing
- RBS2418
- Where
- 5 sites in United States, Puerto Rico and 1 more
- Volunteers
- 150 people
- Sponsor
- Riboscience, LLC.
Hepatitis C, Chronic
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
This is a randomized, open-label, multinational study designed to evaluate the "standard" regimen, PegIntron 1.5 µg/kg subcutaneously once weekly plus ribavirin 800-1200 mg daily [Arm PEG2b 1.5/R (24 weeks)], compared to a lower…
- Trial name
- NCT00302081
- Testing
- peginterferon alfa-2b (SCH 54031), ribavirin (SCH 18908)
- Volunteers
- 696 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepatitis C
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PegIntron plus Rebetol combination therapy administered to patients with chronic hepatitis C.
- Trial name
- NCT00724230
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 505 people
- Sponsor
- Merck Sharp & Dohme LLC
UC - Ulcerative Colitis
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of LYNC-101 for Injection in Healthy Adult Participants
This Phase I study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and cytokine profiles of LYNC-101 for Injection in healthy adult participants.
- Trial name
- NCT07505030
- Testing
- LYNC-101
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- LyncBio Therapeutics Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Acute Bacterial Infections, Acute Viral Infections
300 Antibody Diagnostic Test Kit
For the development of a Point of Care IVD test kit for acute phase disease detection against a variety of bacterial and viral infections.
- Trial name
- Antibody 300 (NCT01646411)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The Plasma Source
Depressive Symptoms, Major Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Cardiology and Gastroenterology
The primary aim of this pilot study is to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for symptoms of…
- Conditions
- Depressive Symptoms, Major Depressive Disorder, Depression, Cardiology
- Trial name
- NCT05461599
- Testing
- SparkRx Mobile App
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Limbix Health, Inc.
Hepatitis C, Chronic
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a [Pegasys] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on…
- Trial name
- NCT01087944
- Testing
- Autoinjector, Pre-filled syringe
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Gastric Ulcer
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
The purpose of this study is to investigate the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with gastric ulcer.
- Trial name
- NCT01452711
- Testing
- TAK-438, Lansoprazole
- Where
- 64 sites in Japan
- Volunteers
- 482 people
- Sponsor
- Takeda
Colorectal Cancer
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and…
- Trial name
- NCT01116271
- Testing
- AZD6244, Irinotecan
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
IPMN, Pancreatic, Pancreas Cancer
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
In this study, LINFU® will be evaluated in patients who have been identified with IPMN to determine if it can be used to help identify early, pancreatic ductal adenocarcinoma and its noninvasive precursor lesions (dysplasia).
- Conditions
- IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
- Trial name
- NCT06276764
- Testing
- LINFU®
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Chronic Hepatitis C
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
This study will examine the effectiveness of 15 days of therapy with SCY-635 in reducing hepatitis C virus (HCV) RNA levels.
- Trial name
- NCT01290965
- Testing
- SCY-635
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Scynexis, Inc.
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Oral Mucositis, Nausea
ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial
RATIONALE: Polymerized (cross-linked) sucralfate malate paste (ProThelial) may be an effective single therapy approach for the management of chemoradiation mucositis, treating and preventing its occurrence in the oral cavity…
- Conditions
- Oral Mucositis, Nausea, Vomiting, Diarrhea
- Trial name
- NCT02016807
- Testing
- ProThelial
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Ashley Downs Bioscience
Irritable Bowel Syndrome
Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study
The purpose of this study is to evaluate the efficacy of a treatment with Lactobacillus casei DG in the reduction of the painful symptoms in patients affected by irritable bowel syndrome.
- Trial name
- NCT02077699
- Testing
- Lactobacillus casei DG
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- SOFAR S.p.A.
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Cystic Fibrosis
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
This study evaluated the safety and pharmacokinetics of multiple ascending doses of VX-440 in combination with tezacaftor/ivacaftor (TEZ/IVA) (triple combination [TC]) administered for 13 days to healthy male and female subjects
- Trial name
- NCT03486236
- Testing
- VX-440, TEZ, IVA
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Crohn's Disease
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment…
- Trial name
- COMPAS (NCT03559660)
- Testing
- Certolizumab Pegol
- Sponsor
- UCB Biopharma SRL
Haemophilus Influenzae Type b, Diphtheria
Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.
A trial to characterize the immunogenicity of 2 different formulations of a vaccine from GSK Biologicals, including the following five antigens: diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b.
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Tetanus, Hepatitis B
- Trial name
- NCT00316680
- Testing
- Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine
- Where
- Dominican Republic
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.